Dr. Ara A Ajemian, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 85 Chestnut Ridge Rd, Suite 111, Montvale, NJ 07645 Phone: 201-930-0700 |
Dr. Margaret Rodriquez, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 85 Chestnut Ridge Rd, Suite 111, Montvale, NJ 07645 Phone: 201-930-1700 |
News Archive
The bill rushed through the House of Representatives by voice vote yesterday to patch Medicare regulations includes a highly controversial provision that has nothing to do with Medicare, and that would subject people in crisis to forced treatment.
Rocio Sotillo, a staff scientist at the European Molecular Biology Laboratory (EMBL) in Monterotondo, is one of 28 outstanding young biomedical scientists who have been honoured with a Howard Hughes Medical Institute (HHMI) International Early Career Scientist award this year.
Novo Nordisk, a global healthcare company, announced today the U.S. Food and Drug Administration (FDA) approved the new drug application for Victoza® (liraglutide [rDNA origin] injection), the first once-daily human glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2 diabetes. Victoza is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.
In an essay adapted for Forbes magazine from a speech given at the Forbes 400 Summit on Philanthropy in June, Bill Gates, co-chair of the Bill & Melinda Gates Foundation, discusses how "innovations for the poor suffer from ... market limitations" and his idea of "catalytic philanthropy." Gates writes, "The market is not going to place huge bets on research when there are no buyers for a breakthrough. This explains why we have no vaccine for malaria today, even though a million people die from it every year."
Trovagene, Inc., a developer of cell-free molecular diagnostics, today announced the launch of a study that aims to determine utility of the Company's Precision Cancer Monitoring (PCM) technology for predicting response to treatment in advanced melanoma patients receiving one or a combination of the novel immunotherapy agents Yervoy (ipilumumab), a CTLA-4 inhibitor, and Opdivo (nivolumab), a PD-1 inhibitor.
› Verified 1 days ago